Abstract:Background: CEP290-associated inherited retinal degeneration causes severe early-onset vision loss due to pathogenic variants in CEP290. EDIT-101 is a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) gene-editing complex designed to treat inherited retinal degeneration caused by a specific damaging variant in intron 26 of CEP290 (IVS26 variant). Methods: We performed a phase 1-2, open-label, single-ascending-dose study in which persons 3 years of age or older with CEP290-associated inherited retinal degeneration caused by a homozygous or compound heterozygous IVS26 variant received a subretinal injection of EDIT-101 in the worse (study) eye. The primary outcome was safety, which included adverse events and dose-limiting toxic effects. Key secondary efficacy outcomes were the change from baseline in the best corrected visual acuity, the retinal sensitivity detected with the use of full-field stimulus testing (FST), the score on the Ora-Visual Navigation Challenge mobility test, and the vision-related quality-of-life score on the National Eye Institute Visual Function Questionnaire-25 (in adults) or the Children's Visual Function Questionnaire (in children). Results: EDIT-101 was injected in 12 adults 17 to 63 years of age (median, 37 years) at a low dose (in 2 participants), an intermediate dose (in 5), or a high dose (in 5) and in 2 children 9 and 14 years of age at the intermediate dose. At baseline, the median best corrected visual acuity in the study eye was 2.4 log10 of the minimum angle of resolution (range, 3.9 to 0.6). No serious adverse events related to the treatment or procedure and no dose-limiting toxic effects were recorded. Six participants had a meaningful improvement from baseline in cone-mediated vision as assessed with the use of FST, of whom 5 had improvement in at least one other key secondary outcome. Nine participants (64%) had a meaningful improvement from baseline in the best corrected visual acuity, the sensitivity to red light as measured with FST, or the score on the mobility test. Six participants had a meaningful improvement from baseline in the vision-related quality-of-life score. Conclusions: The safety profile and improvements in photoreceptor function after EDIT-101 treatment in this small phase 1-2 study support further research of in vivo CRISPR-Cas9 gene editing to treat inherited retinal degenerations due to the IVS26 variant of CEP290 and other genetic causes. (Funded by Editas Medicine and others; BRILLIANCE ClinicalTrials.gov number, NCT03872479.).

Attitudes of people with inherited retinal conditions toward gene editing technology

Gene editing technology: Towards precision medicine in inherited retinal diseases

Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in Australia

A multinational survey of potential participant perspectives on ocular gene therapy

The Potential of Gene Editing Technologies in the Treatment of Hereditary Retinal Diseases

Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing

Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress

Patient experiences and perceived value of genetic testing in inherited retinal diseases: a cross-sectional survey

Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing

New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies

Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases

Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy

Systematic Evaluation Of A Targeted Gene Capture Sequencing Panel For Molecular Diagnosis Of Retinitis Pigmentosa

CRISPR DNA Base Editing Strategies for Treating Retinitis Pigmentosa Caused by Mutations in Rhodopsin

Gene Editing for CEP290-Associated Retinal Degeneration

Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives

Genetic Testing Experiences of People Living with Inherited Retinal Degenerations: Results of a Global Survey

Navigating the Genetic Landscape: A Comprehensive Review of Novel Therapeutic Strategies for Retinitis Pigmentosa Management

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

Retinitis Pigmentosa Patients' Attitudes Toward Participation in Retinal Prosthesis Trials.

Gene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration